MedDataX Logo

Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo

NCT ID: NCT07044141

Last Updated: 2025-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Total 20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine 50mg twice daily. 10 will be given tofacitinib 5mg twice daily. For 6 months

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Azathioprine is an immunomodulator used in treatment of vitiligo

Group Type ACTIVE_COMPARATOR

Azathioprine

Intervention Type DRUG

azathioprine 50mg twice daily will be given

Group B

Tofacitinib It is a Janu kinase pathway inhibitor

Group Type ACTIVE_COMPARATOR

Tofacitinib

Intervention Type DRUG

It is a janus kinase inhibitor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Azathioprine

azathioprine 50mg twice daily will be given

Intervention Type DRUG

Tofacitinib

It is a janus kinase inhibitor

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient of vitiligo with any VASI both genders 18 to 60yrs

Exclusion Criteria

* pregnancy/lactation Hyerlipidrmia Patient on immunemodulator Histry pf tuberculosis Immunocompromised patients
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lahore General Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr ayesha wahid

Dr saadiya siddiqui

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lahore general.hospital

Lahore, Punjab Province, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dermatology LGH

Identifier Type: -

Identifier Source: org_study_id